ARTICLE | Company News
OncoFusion reacquires BET candidates
January 16, 2016 2:34 AM UTC
OncoFusion Therapeutics Inc. (Ann Arbor, Mich.) said it reacquired rights from Medivation Inc. (NASDAQ:MDVN) to "certain compounds" targeting the BET bromodomain superfamily. OncoFusion said it plans to begin clinical trials of at least one candidate.
Medivation licensed the BET portfolio in 2014 (see BioCentury Innovations, May 8, 2014). ...